Pharvaris (PHVS) News Today $29.78 +2.04 (+7.34%) As of 04:00 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share News and Trends Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest Pharvaris Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2026 September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 Time Period More filters Fewer filters Done Pharvaris (NASDAQ:PHVS) Shares Climb 7.4% - Time to Buy?1 hour ago | marketbeat.comPharvaris FY2028 Earnings Forecast Boosted by HC WainwrightOctober 10, 2026 | americanbankingnews.comPharvaris' Rare Disease Drug Meets Primary, Secondary Goals in Phase 3 TrialOctober 9, 2026 | finance.yahoo.comPhase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The LancetOctober 9, 2026 | markets.businessinsider.comPharvaris' Deucrictibant XR Cuts HAE Attack Rate By 83%; Plans NDA Filing In H1 2027October 9, 2026 | rttnews.comPhase 3 Study Results Highlighting Deucrictibant's Rapid and Sustained Efficacy in Treating HAE Attacks Published in The LancetOctober 8, 2026 | globenewswire.comCould Real-World HAE Oral Preference Data Be a Pivotal Signal for Pharvaris' (PHVS) Strategy?October 8, 2026 | finance.yahoo.comPharvaris Stock Gets Higher EPS Forecast from HC WainwrightOctober 8, 2026 | marketbeat.comPharvaris Stock Earnings Estimates Reduced by HC WainwrightOctober 7, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: AgomAb Therapeutics NV ADR (AGMB) and Pharvaris (PHVS)October 7, 2026 | theglobeandmail.comPharvaris Study Shows HAE Patients Prefer Oral Prophylaxis Over InjectionsOctober 5, 2026 | rttnews.comReal-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in TherapyOctober 5, 2026 | globenewswire.comPharvaris N.V. (NASDAQ:PHVS) Stock Has Consensus Price Target of $59.87September 29, 2026 | marketbeat.comBank of America Corp DE Makes New Investment in Pharvaris N.V. $PHVSSeptember 29, 2026 | marketbeat.comInsider Selling: Pharvaris (NASDAQ:PHVS) Director Sells $395,575.45 in StockSeptember 25, 2026 | marketbeat.comPharvaris (NASDAQ:PHVS) Director Sells $28,952.00 in StockSeptember 25, 2026 | insidertrades.comJohannes Gerardus Chri Schikan Sells 800 Shares of Pharvaris (NASDAQ:PHVS) StockSeptember 24, 2026 | marketbeat.comPharvaris (NASDAQ:PHVS) CFO David Nassif Sells 6,000 Shares of StockSeptember 24, 2026 | insidertrades.comPharvaris (NASDAQ:PHVS) CFO Sells $218,820.00 in StockSeptember 23, 2026 | marketbeat.comRobert Glassman Sells 14,493 Shares of Pharvaris (NASDAQ:PHVS) StockSeptember 22, 2026 | insidertrades.comPharvaris (NASDAQ:PHVS) Director Sells $558,850.08 in StockSeptember 21, 2026 | marketbeat.comAnne Lesage Sells 20,000 Shares of Pharvaris (NASDAQ:PHVS) StockSeptember 21, 2026 | marketbeat.comPharvaris (NASDAQ:PHVS) Director Elisabeth Bjork Sells 52,500 SharesSeptember 21, 2026 | marketbeat.comPharvaris (NASDAQ:PHVS) President Peng Lu Sells 100,000 SharesSeptember 21, 2026 | marketbeat.comInsider Selling: Pharvaris (NASDAQ:PHVS) Director Sells $7,000,000.00 in StockSeptember 21, 2026 | marketbeat.comWhat Does Pharvaris (PHVS) Phase 3 HAE Success Mean Now?September 19, 2026 | finance.yahoo.comEngineers Gate Manager LP Makes New Investment in Pharvaris N.V. $PHVSSeptember 19, 2026 | marketbeat.comRobert Glassman Sells 8,667 Shares of Pharvaris (NASDAQ:PHVS) StockSeptember 18, 2026 | insidertrades.comInsider Selling: Pharvaris (NASDAQ:PHVS) Insider Sells 6,090 SharesSeptember 17, 2026 | insidertrades.comInsider Selling: Pharvaris (NASDAQ:PHVS) CEO Sells $90,265.40 in StockSeptember 16, 2026 | insidertrades.comPharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 15, 2026 | seekingalpha.comPharvaris NV consensus price target raised 20.08% to $59.77September 15, 2026 | msn.comInsider Selling: Pharvaris (NASDAQ:PHVS) Insider Sells 30,000 Shares of StockSeptember 15, 2026 | insidertrades.comAnalysts Conflicted on These Healthcare Names: Xeris Pharmaceuticals (XERS) and Pharvaris (PHVS)September 12, 2026 | theglobeandmail.comPharvaris (NASDAQ:PHVS) Director Sells $300,400.00 in StockSeptember 12, 2026 | insidertrades.comPharvaris (PHVS) Gets a Buy from Leerink PartnersSeptember 11, 2026 | theglobeandmail.comPharvaris (PHVS) Reports an 83% HAE Attack-Rate Reduction. Can Oral Convenience Win?September 10, 2026 | insidermonkey.comPharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary Angioedema - SlideshowSeptember 10, 2026 | seekingalpha.comRBC Capital Sticks to Its Buy Rating for Pharvaris (PHVS)September 10, 2026 | theglobeandmail.comPharvaris (NASDAQ:PHVS) President Sells 15,000 SharesSeptember 10, 2026 | insidertrades.comPharvaris Could Gain Hereditary Angioedema Market Share on Deucrictibant XR Data, RBC SaysSeptember 9, 2026 | finance.yahoo.comPharvaris: 'Strong Buy' Based On Deucrictibant PDUFA And Prophylaxis Trial WinSeptember 9, 2026 | seekingalpha.comWedbush Reaffirms Outperform Rating On Pharvaris; PT $42 After Positive Phase 3 CHAPTER-3 DataSeptember 9, 2026 | rttnews.comRBC Raises Price Target on Pharvaris to $62 From $52, Keeps Outperform, Speculative RiskSeptember 9, 2026 | marketscreener.comMPharvaris Shares Jump 16% On Positive Phase 3 HAE Study ResultsSeptember 8, 2026 | rttnews.comPharvaris Shares Surge 27% After Deucrictibant Phase 3 Trial Meets Primary EndpointSeptember 8, 2026 | finance.yahoo.comBiotech stocks, with 'blowout' and 'bull case' results, rocket to record highsSeptember 8, 2026 | msn.comPharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary Angioedema TranscriptSeptember 8, 2026 | seekingalpha.comPharvaris Unveils CHAPTER-3 Phase 3 Topline Data and HAE Pipeline MilestonesSeptember 8, 2026 | tipranks.comPharvaris Reports Positive Phase 3 CHAPTER-3 Results For Deucrictibant XR In HAE ProphylaxisSeptember 8, 2026 | rttnews.com Pharvaris Media Mentions By Week Pharvaris Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PHVS News Sentiment▼0.000.48▲Average Healthcare News Sentiment Pharvaris News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PHVS Articles This Week▼15▲PHVS Articles Average Week Pharvaris Trends on MarketBeatThis week vs. last weekNew Followers1Searches1-50%Page Views2,514-18% Get Pharvaris News Delivered to You Automatically Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Cytokinetics News Abivax News Ionis Pharmaceuticals News Praxis Precision Medicines News Alkermes News Iovance Biotherapeutics News GRAIL News Kiniksa Pharmaceuticals International News Ligand Pharmaceuticals News Rhythm Pharmaceuticals News News and Trends Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Pharvaris dated 10/19/2026. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharvaris With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
